Next Investors logo grey

MyFiziq teams up with BioMorphik to share technologies on its medical health and wellness platform


Published 10-AUG-2020 10:46 A.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

MyFiziq Limited (ASX: MYQ) has signed a binding term sheet with BioMorphikk Pty Ltd, an Australian based behavioural change and technology company that has developed a medical health and wellness platform.

This platform is the bridge between medical and health/wellness. It aims to reduce health costs at all levels of society from the individual, to healthcare and insurance systems, as well as governments.

BioMorphik and MyFiziq will collaborate to integrate MyFiziq’s body tracking application into all of BioMorphik’s verticals, commencing with an initial integration into its pre-emptive health platform over the coming months.

BioMorphik has created a pre-emptive health platform founded on the basis that consistent and early management of health and fitness at younger ages has a compounding effect on health later in life.

Through smaller, constant, micro-interventions BioMorphik can drastically improve lifetime health, reduce the need for medical interventions, and save costs and resources for the user and health systems.

1 - myq.PNG

Reduces strain on public and private health infrastructure

The goal of Biomorphik’s pre-emptive health platform is to improve user quality of life, reduce spending on medical treatment, and reduce interactions with the medical system.

With global medical facilities and personnel stretched to their limits and further compounded by a significant worldwide economic downturn and job losses as a result of COVID-19, there should be significant demand for the group’s product offering.

Biomorphik’s solution is a well-designed platform with the intention to improve health outcomes, saving individuals, insurers and governments’ substantial costs, helping to reduce the burden on the global medical facilities and supply chains.

MyFiziq will be an integral part of the BioMorphik direct to consumer offering as the primary checkpoint of identifying and tracking the markers for chronic disease, as well as dimensional and body composition change.

As outlined in the binding terms sheet, the parties will work together to deliver a market-ready integration into the BioMorphik platform by the March quarter of 2021.

In parallel, the parties have agreed to conclude all formal agreements within 60 days of signing the binding terms sheet.

Under the terms of the agreement, BioMorphik has undertaken to deliver a minimum of 100,000 active users within the first 12 months of launch.

Corporate activity highlighted by US$18.5 billion acquisition of Livongo

Commenting on this development and in particular its timing in the current environment MyFiziq chief executive Vlado Bosanac said, “Due to the COVID-19 pandemic, the world has experienced a surge in m-Health, telehealth, virtual care and preventative health investment.

‘’This week alone, we saw Teledoc acquire Livongo for USD$18.5 billion.

‘’BioMorphik’s behavioural based program targets smaller interventions prior to current preventative healthcare solutions, which is unique and innovative in this urgently needed market segment.

‘’With medical facilities and supply chains strained worldwide as a result of current pandemic, BioMorphik has identified, developed and entered the market with a dynamic and well-resourced offering.

‘’I am pleased to be working with Nathaniel Peek (CEO BioMorphik) and the BioMorphik team to provide an urgently needed, unique behavioural based, pre-emptive health solution that focuses on reducing costs at all levels of the health, wellness and medical supply chain from the user/patient, all the way to the medical provider, insurer and even at government levels.”

Endorsing Bosanac’s comments and underlining the complementary nature of both technologies, Peek said, ‘’Through integrating MyFiziq’s technology into our platform, we now have the capability to more regularly and cost effectively understand user and patient body composition information as well as their risks of chronic disease in real time, capturing their body scans from the privacy of their own home, significantly broadening our B2B (business to business) and B2C (business to consumer) customer reach.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.